Alprostadil for acute cerebral infarction

AIM: To observe the efficacy of alprostadil (Lipo prostaglandin E 1) in treating acute cerebral infarction. METHODS: Ninety eight patients with acute cerebral infarction were divided into two groups. Alprostadil group of 52 patients (M 30, F 22; age 64 a± s 9 a) received alprostadil 10 μg in sodium chloride injection 10 mL, iv, qd, and panax notoginseng saponins 0.6 g in sodium chloride injection 250 mL iv, gtt, qd, and conventional therapy (mannitol, piracetam, citicoline, ATP, coenzyme A, nimodipine, etc.) for 2 wk. Other 46 patients of the control group (M 27, F 19; age 65 a±11 a) only received panax notogmseng saponins 0.6 g in 5% glucose injection 250 mL or sodium chloride injection 250 mL iv.gtt,qd, and conventional therapy for 2 wk. RESULTS: The total effective rate in the alprostadil group (94%) was higher than that in the control group (89%, P 0.05). Changes of all hemorheological characters were very significant in two groups ( P 0.01). CONCLUSION: alprostadil (lipo prostagland in E 1) is a valuable drug in treating acute cerebral infarction.